Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TOP2A | P11388 | 2/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7502612 | 0.92 | ADRB2 (0.33) | ADRB2 | |
| SCHEMBL7847474 | 0.88 | ADRB2 (0.48) | ADRB2KCNH2KDM4EHPGDALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL7846826 | 0.85 | ADRB2 (0.40) | ADRB2KCNH2KDM4EHPGDALDH1A1 | |
| SCHEMBL7847006 | 0.83 | ADRB2 (0.44) | ADRB2KCNH2KDM4EHPGDALDH1A1 | |
| SCHEMBL7846534 | 0.83 | ADRB2 (0.42) | ADRB2KCNH2KDM4EHPGDALDH1A1 | |
| SCHEMBL7835489 | 0.81 | ADRB2 (0.43) | ADRB2KCNH2KDM4EHPGDALDH1A1 | |
| SCHEMBL7846922 | 0.81 | KCNH2 (0.46) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL7494366 | 0.81 | KCNH2 (0.46) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL7836504 | 0.81 | KCNH2 (0.46) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| SCHEMBL7836509 | 0.81 | KCNH2 (0.46) | KCNH2KDM4EHPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | PETERSEN UWE (DE) | 2001-11-01 | — | — | US | disclosed |
| US-6288081-B1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolone carboxylic acid and naphthyridone carboxylic acid derivatives for treating Helicobacter pylori infections and the gastroduodenal diseases associated therewith | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036941-A1 | Use of 7-(1-aminomethyl-2-oxa-7-aza-bicyclo[3.3.0]oct-7-yl)-quinolonecarboxylic acid and -naphthyridonecarboxylic acid derivatives for the therapy of Helicobacter pylori infections and associated gastroduodenal disorders | OXER1, AOC3, PAM | ADRB2 2223/4885KCNH2 3936/4885KDM4E 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.